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CHAPTER 1: INTRODUCTION 
 
Tuberculosis (TB) remains the leading cause of death due to a single infectious agent, 
Mycobacterium tuberculosis (M. tuberculosis).  The disease is a major public health problem 
and is responsible for approximately 1.7 million deaths annually worldwide (Sandgren et al. 
2009).  It ranks number one among causes of death in South Africa (Statistics South Africa 
2014). 
 
The two main outcomes of infection with M. tuberculosis are active disease and latent 
infection (Parrish et al. 1998). Active disease is characterised by the presence of dividing M. 
tuberculosis bacilli able to accumulate mutations leading to resistance.  To avoid treatment 
failure due to mutations in genes coding for drug targets, active TB is treated with a 
combination of four drugs in the first two months of a six month treatment course (Bass et al. 
1994).  In this initiation phase of treatment, the bacterial load is supposed to be high and 
therefore, the number of mutating bacterial cells is also high.  The  four drug treatment 
regimen is based on the reduced likelihood of two or more mutations arising in a single 
bacterium (Johnson et al. 2006).  In contrast with active disease, latent TB infection is 
asymptomatic (Flynn & Chan 2001) and thought to be characterised by dormant, non-
replicating bacilli (Wayne 1994).  Since dormant bacilli are thought to lack the capacity to 
acquire resistance conferring mutations, latent TB is treated by prophylactic therapy using a 
single drug, usually isoniazid (Sterling 2008). 
 
It is well established that there are differences between strains of M. tuberculosis with respect 




globally is the Beijing strain (Bifani et al. 2002; Glynn et al. 2002; Hanekom et al. 2011), 
with other strains predominating in different parts of the world. These successfully spreading 
strains also predominate among the drug resistant cases of TB.  
 
A number of resistant strains are known to circulate within the KwaZulu-Natal province of 
South Africa.  This includes strains of the Beijing genotype and strains of the 
F15/LAM4/KZN (KZN) genotype (Ashiru et al. 2010). Both are found more commonly in 
patients with resistant TB, with the Beijing strain being multidrug resistant (MDR) and the 
KZN strains showing a variety of resistance patterns including extensive drug resistance 
(XDR) and total drug resistance (TDR) (unpublished).  
 
The frequency of mutation acquisition leading to drug resistance is thought to be strain-
dependent (Brown et al. 2010).  Based on the epidemiological association of the Beijing 
strain with multidrug resistance globally, it is presumed to acquire resistance conferring 
mutations at higher frequencies than others.  However, there is significant discordance in the 
literature regarding strain-based mutation acquisition (Werngren & Hoffner 2003; de 
Steenwinkel et al. 2012; Ford et al. 2013). 
 
Given the limited clarity regarding the mutational capacity between strain families and during 
latent infection, the mutation frequencies will be compared between isolates of the Beijing 
and KZN lineages, each under aerobic and anaerobic conditions. For the work presented here, 
anaerobic incubation conditions are proposed as a proxy for latency (Wayne & Hayes 1996; 





CHAPTER 2: LITERATURE REVIEW 
 
2.1. Burden of tuberculosis in South Africa 
Decades after the introduction of the first anti-tuberculosis drugs, tuberculosis (TB) remains 
the leading cause of death due to an infectious agent in South Africa (Statistics South Africa, 
2014).  Of particular concern is the emergence of resistant strains, which greatly threaten TB 
control programmes (Moodley et al. 2011).  These include multidrug-resistant (MDR) 
organisms, which are resistant to the most effective first-line drugs isoniazid and rifampicin, 
and extensively drug-resistant (XDR) organisms, which are MDR with additional resistance 
to one of the second-line injectables (amikacin, capreomycin or kanamycin) and the 
fluoroquinolones (Ioerger et al. 2009).  Compounding this, totally drug resistant (TDR) M. 
tuberculosis strains have been reported in Iran (Velayati et al. 2009), Italy (Migliori et al. 
2007), India (Udwadia et al. 2012) and most recently, South Africa (Klopper et al. 2013).  
South Africa ranks amongst the countries with the highest burden of TB (Figure 2.1). 
 
KwaZulu-Natal currently ranks as the province with the highest mortality rate due to TB in 
South Africa (Gandhi et al. 2014).  The two most predominant strains currently circulating 
within this province are the W-Beijing strain and the F15/LAM4/KZN (KZN) strain (Ashiru 





Figure 2.1: Estimated TB incidence including MDR and XDR in 2012 
(World Health Organization 2013) 
 
 
2.2. Mycobacterium tuberculosis strain families in South Africa 
 
2.2.1. The Beijing family 
The Beijing strain was first identified via IS6110 restriction fragment length polymorphism 
(RFLP) fingerprint analysis in 1995 in China, and was found to be similarly distributed in 
adjacent countries including South Korea and Thailand (van Soolingen et al. 1995).  Based on 
the high frequency of isolates observed in the Beijing region, this family of strains was 





The first clonal outbreak of MDR-TB was observed in New York City in the early 1990s 
(Frieden et al. 1993; Bifani et al. 1996).  The causative strain was found to be resistant to 
first-line therapy, and was associated with rapid spread in populations with a high human 
immunodeficiency virus (HIV) prevalence, including prisons (Valway et al. 1994).  This 
strain, initially designated strain “W”, was later identified as the Beijing strain, and was 
found to be responsible for numerous outbreaks in South-East Asia (van Soolingen et al. 
1995; Agerton et al. 1999).      
 
Many epidemiological studies have demonstrated high levels of resistance associated with the 
disease outbreaks caused by strains belonging to the Beijing family (Bifani et al. 2002; 
Brown et al. 2010). The global dissemination of the Beijing family of strains (Figure 2.2), 
and the concomitant emergence of drug resistance within this family, has led to its 










Figure 2.2: Global distribution and percentage of tuberculosis cases caused by Beijing 
strains.  The size of the circle represents the percentage of TB cases due to the Beijing 
genotype.  The colour of the circle represents the distribution and association of these Beijing 
genotype strains with drug resistance.  Blue: stable distribution with no known association 
with drug resistance.  Red: increasing distribution with associated drug resistance.  Green: 
increasing distribution with no known association with drug resistance.  Yellow: Beijing 
genotype is absent.  Striped: distribution and association with drug resistance unknown.     
   In South Africa, such cases are increasing in distribution and are also associated with 
resistance. 
(European Concerted Action on New Generation Genetic Markers and Techniques for the 





2.2.2. The KZN family 
Following the advance of the HIV epidemic in South Africa, high rates of TB disease were 
reported locally, with the highest rate reported in KwaZulu-Natal (Abdool Karim et al. 2009).  
The first reported cases of XDR-TB in South Africa were identified in KwaZulu-Natal in 
2005 (Gandhi et al. 2006).  Spoligotyping of isolates from infected patients within KwaZulu-
Natal revealed that one particular genotype was responsible for these infections (Gandhi et al. 
2006).  These isolates were resistant to isoniazid, rifampicin, the fluoroquinolones and 
kanamycin and were thus termed “extensively drug resistant” (XDR).  Based on its origin, the 
causative strain was termed the “KwaZulu-Natal strain” (World Health Organization 2006; 
Pillay & Sturm 2007).  Based on spoligotype patterns (Streicher et al. 2007), this strain was 
later classified as the F15/LAM4/KZN strain (Pillay & Sturm 2007), henceforth referred to as 
the KZN strain.   
 
The first multidrug resistant variant of the KZN strain was identified in 1994, and exhibited 
resistance to isoniazid, rifampicin and streptomycin (Pillay & Sturm 2007).  By means of 
RFLP analysis, it was shown that this variant acquired resistance to both first and second-line 





Figure 2.3: Progression of the F15/LAM4/KZN strain from multidrug resistant to extensively 
drug resistant (Pillay & Sturm 2007) 
 
An important observation of this study was that the first multidrug resistant variant, from 
which extensive drug resistance developed in 2001, harboured additional resistance to 
streptomycin.  This suggests a possible association between streptomycin resistance and 
extensive drug resistance within the KZN family.  Furthermore, this suggests that the addition 
of streptomycin to the first-line regimen for patients that needed retreatment was the driving 
force for the development of the XDR form of the KZN strain (Pillay & Sturm 2007).  While 
epidemiological studies have shown an association between M. tuberculosis genotypes and 
resistance, the direct link between mutational capacity and levels of resistance development 




2.3. Development of anti-tuberculosis therapy 
Treatment of tuberculosis differs from that of other bacterial infections.  M. tuberculosis is 
slow-growing, which may affect drug activity.  In addition, the characteristic lipid-rich cell 
wall of M. tuberculosis is thought to render the bacterium impermeable to polar antibiotics, 
including beta-lactam drugs (Finch 1986). 
 
The discovery of streptomycin in 1946 marked the beginning of antibiotic-based anti-
tuberculosis therapy (Youmans & Feldman 1946), with early clinical studies showing a 
reduction in bacterial load and mortality in patients placed on streptomycin monotherapy.  
However, this was followed by relapse, accompanied by the appearance of streptomycin 
resistance (Crofton & Mitchison 1948).  This promptly led to the introduction of combination 
therapy using streptomycin and para-aminosalicylic acid (PAS), in order to reduce the 
emergence of resistance (Graessle & Pietrowski 1949; Fox & Sutherland 1956).   
 
Isoniazid was discovered shortly afterwards in 1952 (Knox et al. 1952), and has since 
remained the backbone of anti-tuberculosis therapy due to its effective early bactericidal 
activity, low minimum inhibitory concentration (MIC) and minimal side effects.  Early 
clinical studies using combinations of streptomycin, PAS and isoniazid led to the design of 
three-drug regimes, intended to reduce the occurrence of resistance (Stahle 1958; Mitchison 
& Davies 2012).  The introduction of pyrazinamide, rifampicin and ethambutol further 
increased options for anti-tuberculosis therapy, since each drug targets a unique component 





After numerous clinical trials using a range of drug combinations to reduce both the 
occurrence of resistance and the duration of therapy, it was concluded that for anti-
tuberculosis therapy to be effective, a minimum of three drugs was needed: isoniazid, 
rifampicin and pyrazinamide (Iseman 2002; Mitchison & Davies 2012).  In areas with high 
levels of monoresistance to one of these drugs, the addition of ethambutol was recommended.  
Currently, the WHO recommends a 6-month treatment regime comprising of 2 months of 
isoniazid, rifampicin, pyrazinamide and ethambutol, followed by a 4-month continuation 
phase of isoniazid and rifampicin (Bass et al. 1994).  
 
2.4. Drug resistance in Mycobacterium tuberculosis 
Following his discovery of the first antibiotic, Sir Alexander Fleming advised that “misuse of 
antibiotics could result in selection for resistant bacteria” (Bhagwati 2012).  To date, despite 
the range of antituberculosis drugs and treatment options available, multidrug-resistant 
(MDR), extensively drug-resistant (XDR) and totally drug-resistant (TDR) M. tuberculosis 
strains have emerged.  These resistant strains pose a major threat to the global control of 
tuberculosis.   
 
Drug-resistance in bacteria typically arises via a number of different mechanisms including 
the horizontal transfer of resistance genes and chromosomal mutations (Martinez & Baquero 
2000; Livermore 2003).  However, M. tuberculosis has a unique cell wall which is thought to 
render the former mechanism impossible (Pillay & Sturm 2007).  Additionally, there exists 
very little evidence to suggest that M. tuberculosis contains plasmids (Zainuddin & Dale 
1990), thereby diminishing the possibility of inter-bacterial exchange of resistance genes.  In 




the special cell wall of mycobacteria allows only for the specialised bacteriophages known as 
mycobacteriophages to infect this group of bacteria.  Therefore, exchange of genes through 
transduction with bacteria other than mycobacteria cannot occur.  Resistance in M. 
tuberculosis is therefore considered to develop predominantly via spontaneous chromosomal 
mutations (Gillespie 2002; Ford et al. 2011; Almeida Da Silva & Palomino 2011).   
 
Mutations can arise non-specifically, either directly via oxidative damage, or indirectly via 
errors in DNA replication (Dwyer et al. 2009).  Consequently, drug resistance arises if these 
mutations occur in regions coding for a specific drug target.  Such mutations confer a 
selective advantage (Martinez & Baquero 2000) and are not directed (Pope et al. 2008).  
Antimicrobial drugs target functions that are essential for growth and multiplication of the 
bacterial cell.  Mutations in genes coding for drug targets will lead to resistance if the 
mutation results in a change in the target molecule preventing inactivation by the drug 
without affecting the viability of the bacterial cell.  Since resistance-conferring mutations 
interfere with functions essential for bacterial growth, many of these are lethal and thus, 
resistance only becomes apparent if such interferences are non-lethal (Martinez & Baquero 
2000).  As with all bacterial species, drug resistance in M. tuberculosis arises via interplay 
between bacterial-determined factors and host-determined factors. 
 
2.4.1. Bacterial determinants 
 
2.4.1.1. Prokaryotic DNA Polymerase 
Prokaryotic DNA Polymerase is responsible for the incorporation of nucleotides into the 




to misincorporate nucleotides (Fujii et al. 1999), inducing mutations at a frequency of one per 
10
5
 base pairs (Kunkel 2004).  While such low fidelity DNA replication plays a role in 
maintaining genetic variation, resistance will arise if mutations occur in a gene coding for a 
specific drug target.  
 
2.4.1.2. Reactive Oxygen Species  
The three main sources for oxidative stresses leading to DNA damage are hydrogen peroxide 
(H2O2), superoxide radicals (O2·-) and hydroxyl radicals (OH·) (Dwyer et al. 2009).  These 
reactive oxygen species (ROS) are typically formed as by-products of catabolism in the 
presence of oxygen (Sakai et al. 2006).  Exposure to endogenous ROS does not necessarily 
result in mutations, since many bacteria contain detoxifying enzymes to convert these ROS 
into their non-reactive form (Sakai et al. 2006).  These include superoxide dismutase, which 
hydrolyses superoxide to hydrogen peroxide and oxygen, and catalase, which hydrolyses 
hydrogen peroxide to oxygen and water (Dwyer et al. 2009).  In contrast, there are no 
enzymes which are able to detoxify OH·, which is consequently able to directly induce DNA 
damage (Imlay 2003). 
 
2.4.1.3. Reactive Nitrogen Species 
An alternative for ROS-induced mutagenesis is mutagenesis caused by reactive nitrogen 
species (RNS), produced following anaerobic respiration.  RNS may alternatively be 





2.4.1.4. Defective DNA repair systems 
Exposure to endogenous ROS or RNS is known to induce DNA damage resulting in a range 
of mutations (Bjelland & Seeberg 2003).   The most common of these DNA lesions is 
formation of 8-oxoguanine (Dwyer et al. 2009).  This oxidised guanine base is able to 
erroneously pair with adenine instead of cytosine during DNA replication, and is also subject 
to further damage by ROS and RNS.   
 
In order to eliminate such bases, the 8-oxoguanine elimination system, comprising of the 
following components, is employed:    
1. MutM glycosylase: eliminates 8-oxoguanine adducts 
2. MutY glycosylase: eliminates misincorporated adenine nucleotides 
3. MutT phosphatase: converts adenine triphosphate (dATP) to adenine 
monophosphate (dAMP), thereby preventing the erroneous pairing of dATP with 8-
oxoguanine (Maki & Sekiguchi 1992) 
 
Previous in silico analysis revealed that common mismatch repair systems, involved in 
bacterial DNA repair, are absent in M. tuberculosis.  Defects in DNA repair systems may 
play a role in mutator phenotypes and multidrug resistance (Oliver et al. 2000).  Sequencing 
of DNA repair genes in select Beijing isolates revealed mutations in mutT2 and mutT4 
(Ebrahimi-Rad et al. 2003), suggesting a role for these mutator genes in multidrug resistance.  
These mutations were unique to the Beijing family.  However, the mutations were not found 
to be associated with drug resistance (Lari et al. 2006).  Representatives of the KZN family, 




2.4.1.5. Antibiotic-induced ROS formation 
Antibiotic exposure may stimulate the production of ROS (Kohanski et al. 2007).  Kohanski 
et al (2010) have recently shown that antibiotic therapy at low concentrations may stimulate 
random mutagenesis and ROS production, leading to drug resistance (Kohanski et al. 2010).  
Additionally, the authors showed that multidrug resistance may also develop during 
prolonged exposure to suboptimal antibiotic concentrations (Kohanski et al. 2010).  This is 
particularly problematic in the clinical setting, given patient non-compliance, inadequate 
antibiotic therapy, and limited drug accessibility to certain tissues (Kohanski et al. 2010).     
 
2.4.1.6.  Efflux Pumps 
More recently, efflux pumps have been proposed as alternative mechanisms of acquired drug 
resistance in bacteria (Rouveix 2007), including M. tuberculosis (Gumbo et al. 2007; Xin et 
al. 2008; Louw et al. 2009; Louw et al. 2011).  Efflux pumps confer drug resistance by 
actively extruding antibiotics out of the bacterial cell (Rouveix 2007).  The antibiotic 
resistance arrow of time, proposed by Schmalstieg et al (2012), suggests that resistance due 
to efflux pump activity arises shortly after the onset of antibiotic therapy (Schmalstieg et al. 
2012).  Efflux pump activity has been demonstrated against the major anti-tuberculosis drugs, 
namely isoniazid (Gumbo et al. 2007; Machado et al. 2012), rifampicin (Siddiqi et al. 2004; 







2.4.2. Host determinants 
 
2.4.2.1. Inadequate therapy 
Pharmacokinetic variability can lead to suboptimal antibiotic concentrations within the 
patient, resulting in inadequate therapy.  The consequence of this is the selection of drug-
resistant mutants (secondary resistance), which can be followed by the transmission of these 
resistant mutants to close contacts (primary resistance) (Andrews et al. 2008).  In order to 
reduce the emergence of resistance related to inadequate TB therapy, the Directly-Observed 
Treatment, Short Course (DOTS) strategy was implemented in the mid-1990s (Kochi 1997). 
 
2.5. Determining mutation frequencies in bacteria 
A seminal study by Luria and Delbruck in 1947 addressed the question of whether the basis 
of bacterial resistance was the presence of pre-existing mutations, or mutations induced by 
exposure to a selective pressure (Luria & Delbrück 1943).  In the study (Figure 2.4), a 
number of identical, low-density Escherichia coli cultures were prepared and incubated until 
the end of log phase was reached.  Each culture was then plated onto media containing phage 
T1, a bacteriophage that specifically infects E. coli cells.  The authors hypothesized that if 
phage resistance-conferring mutations pre-existed prior to exposure of the selective pressure, 
then there would be a variation in the number of resistant mutants observed between the 
parallel cultures, dependent on when during the bacterial life-cycle the mutation arose.  
Conversely, if the mutations were induced on exposure to the selective pressure, then each 
bacterial cell in the culture would have a similar probability of mutating and thus, there 
would be a similar number of resistant mutants between the parallel cultures (Luria & 




On exposure of the identical E. coli cultures to phage T1, variation in the distribution of T1-
resistant mutants between the parallel cultures was observed.  Based on their hypotheses, this 
fluctuation was thought to be due to pre-existing mutations.  They thus concluded that 
resistance occurs as a result of random, spontaneous mutations prior to and independently of 
the selective pressure.  This method is currently widely applied in determining resistance-







Figure 2.4: Schematic representation of the Fluctuation Analysis. Identical low-density 
cultures are incubated and plated onto selective media to isolate resistant mutants.  Variation 
observed between individual cultures confirms the occurrence of spontaneous resistance 
mutations.  The number of isolated mutants per culture depends on whether the mutation 
occurred early (leading to numerous mutants) or late (leading to few or no mutants) during 
the incubation period. 




2.6. Mutation frequency in Mycobacterium tuberculosis 
Since resistance acquisition in M. tuberculosis is chromosomally encoded (Gillespie 2002; 
Ford et al. 2011; Almeida Da Silva & Palomino 2011), mutation frequencies are commonly 
used as an indicator of resistance development.  The mutation frequency reflects the 
proportion of resistant mutant bacteria within a total population, regardless of the stage at 
which the mutations were acquired during growth of the population (Martinez & Baquero 
2000). 
 
Resistance in M. tuberculosis is acquired to each of the first-line and second-line drugs at 
frequencies ranging between 10
-6
 for isoniazid, to 10
-8
 to rifampicin (Johnson et al. 2006).  
Patients with active TB infection are accordingly treated with multiple drugs, in order to 
eliminate such spontaneously-occurring resistant mutants.  This is based on the probability 
that a single bacterium acquiring resistance against two drugs simultaneously is very low: e.g. 
the probability of a single bacterium acquiring combined resistance to isoniazid and 
rifampicin is approximately 10
-14
, or 1 resistant mutant  in every 10
14
 bacteria (Gillespie 
2002; Sharma & Mohan 2004).    
 
2.6.1. Beijing strains and the hypermutator phenotype 
Using mutation frequency as a marker for drug resistance, the high association of the Beijing 
strains with drug resistance suggests that this strain acquires mutations more frequently than 
other strain families.  Strains with defective DNA repair systems may readily acquire 
mutations and consequently, acquire drug resistance.  Sequencing of putative mutator genes, 
known to play a role in DNA repair, revealed missense mutations and polymorphisms in the 




were unique to the Beijing strains, the idea that strains of this genotype readily acquire 
mutations leading to drug resistance as a result of a poor or defective DNA repair system was 
supported.  This was further reinforced by recent studies, in which a higher association with 
multidrug resistance within the Beijing family was demonstrated (de Steenwinkel et al. 2012; 
Ford et al. 2013).         
 
Challenging this hypothesis, by means of the Fluctuation Analysis, it was found that Beijing 
strains acquire rifampicin resistance-conferring mutations at similar rates to non-Beijing 
strains (Werngren & Hoffner 2003).  This suggests that the association of the Beijing family 
with multidrug resistance is not as a result of a higher mutational capacity.  The basis of the 
association of this family with drug resistance is to date unconfirmed.       
 
2.7. Outcomes of Mycobacterium tuberculosis infection 
Figure 2.5 provides a schematic overview of the different outcomes following infection with 
M. tuberculosis.  Tuberculosis infection begins when droplet nuclei containing M. 
tuberculosis expelled from the lungs of a patient with active tuberculosis are inhaled by a 
healthy human being (Koul et al. 2011).  The clinical outcomes of M. tuberculosis infection 
are either active disease or latent infection (Gengenbacher & Kaufmann 2012), each of which 





Figure 2.5: Possible outcomes of infection with M. tuberculosis. 
(Kumar et al. 2011) 
 
 
2.7.1. Active infection 
Active TB infection is characterised as infection with signs of clinical disease and arises due 
to the inability of the host to develop an immune response able to control the initial infection 
(Gengenbacher & Kaufmann 2012).  In this state, M. tuberculosis multiplies and in doing so, 




To avoid selection of single or dual drug resistance mutants, the patient is treated with a 
combination of four drugs during the initial two months of a six-month course, in order to 
eliminate mutants resulting in drug resistance (Bass et al. 1994).   This assumption is based 
on the fact that it is unlikely that two or more mutations will occur in the same bacterial cell 
(Pillay & Sturm 2007).  In the last 4 months, the bacterial load is thought to be too low for 
mutations to occur at a significant rate.  Continuation treatment is therefore with two drugs 
only. 
 
2.7.2. Latent tuberculosis infection 
Early clinical observations of latent TB (LTBI) infection prompted the first definition of 
latency as “the presence of any tuberculous lesion which fails to produce symptoms of its 
presence” (Amberson Jr 1938).  LTBI is defined as infection with M. tuberculosis in the 
absence of disease indicators, and accounts for approximately 90% of all TB cases.  While 
those harbouring dormant TB are not infectious, they serve as a potential reservoir for disease 
reactivation, followed by further spread (Parrish et al. 1998).  The risk of disease reactivation 
depends on varied factors including the immune status of the infected individual, the 
infecting strain and bacterial load, the geographical location, and environmental factors 
(Sterling 2008). 
   
During LTBI, the bacteria are phagocytosed to form granulomas (Flynn & Chan 2001).  
Within these lesions, the bacteria are thought to be exposed to hostile conditions including 
hypoxia, limited nutrient availability, reactive oxidative species and acidity (Tan et al. 2010; 
Rustad et al. 2009).  Granulomas serve to limit the spread of infection and prevent the 




the bacteria are able to avoid the host defence forces and are presumed to lie dormant.  As a 
result, M. tuberculosis undergoes far less growth and metabolic activity during latent 
infection as compared to active infection.  Due to the reduced or ceased replication rate, they 
are presumed to accumulate fewer mutations (Sterling 2008).  This provides the basis for 
prophylaxis to avoid reactivation of TB by a single drug, usually isoniazid (INH), 
administered over a six to nine month period (Sterling 2008).  While numerous studies have 
afforded a better understanding of the ability of M. tuberculosis to adapt during latent 
infection, the physiological state of the bacterium during this phase in the host remains poorly 
understood (Gomez & McKinney 2004). 
 
Challenging the classic concept of M. tuberculosis infection outcomes, recent evidence 
suggests that the two M. tuberculosis diseases states are not distinct (Barry  3rd et al. 2009; 
Lawn et al. 2011).  This implies that there may be significant overlap between active and 
latent disease states. 
 
2.8. Anti-mycobacterial drugs 
Patients with active TB are treated with a combination of drugs in order to eliminate mutants 
which may lead to drug resistance, since actively dividing bacilli are more likely to acquire 
mutations via error-prone DNA polymerases.  The drugs used are grouped as first-line and 
second-line drugs.  The latter group consists of drugs that are only used when initial treatment 
fails, or in case of established drug resistance.  They are more toxic and less effective than the 






2.8.1.1. Mode of action 
Isoniazid was first demonstrated to show bactericidal activity against M. tuberculosis in 1952  
(Knox et al. 1952; Rattan et al. 1998).  Since then, isoniazid has remained the backbone in the 
treatment of both active disease and latent infection.  Isoniazid is a prodrug which requires 
activation by bacterial catalase-peroxidase, encoded by katG (Zhang et al. 1992). This results 
in the generation of reactive oxygen species which are toxic to the infected cell (Zhang et al. 
1992).  In its active form, isoniazid directly disrupts mycolic acid biosynthesis, which is an 
essential component for the growing M. tuberculosis cell wall.  The target of activated 
isoniazid is inhA, encoded by the inhA gene, which is proposed to play a role in elongation of 
fatty acids during mycolic acid biosynthesis (Banerjee et al. 1994).   
 
The mode of action of isoniazid is summarised in Figure 2.6: 
 





2.8.1.2. Isoniazid Resistance 
The development of isoniazid resistance following isoniazid monotherapy has been well 
documented since its anti-tuberculosis properties were first described (Ogilvie 1954).  Since 
then, numerous studies have shown that M. tuberculosis is able to acquire isoniazid-resistance 
conferring mutations at a frequency of approximately 1x10
-6 
(David 1970; Johnson et al. 
2006), which is the highest of all the anti-tuberculosis drugs.  It is likely that this high 
mutation frequency is dependent upon the large number of isoniazid resistance-associated 
genes (Table 2.1), including those genes coding for products involved in isoniazid activation 
and mycolic acid biosynthesis.   
 
Since catalase-peroxidase is required to activate isoniazid into its toxic form, mutations 
within the katG gene, which encodes catalase-peroxidase, confer high-level isoniazid 
resistance (Ramaswamy & Musser 1998).  High-level isoniazid resistant mutants defective in 
katG activity are thought to rapidly acquire further mutations leading to an elevated mutation 
rate as a result of defective catalase-peroxidase activity, lacking the ability to detoxify ROS 
intermediates including hydrogen peroxide (Zhang et al. 1992).  However, recent data 
suggest that M. tuberculosis isolates with defective catalase-peroxidase activity are able to 
compensate by the upregulation of ahpC (O’Sullivan et al. 2008).  The ahpC gene encodes an 
alkyl hydroperoxide reductase protein, which detoxifies oxidative intermediates in the 
absence of katG activity.       
 
The proposed target of activated isoniazid is inhA, an enoyl-acyl carrier protein (ACP) 
reductase encoded by the inhA gene (Banerjee et al. 1994), which plays a role in mycolic acid 




biosynthesis, eventually leading to cellular death (Timmins & Deretic 2006).  Mutations 
within the inhA gene prevent the binding of isoniazid, leading to low-level resistance (Guo et 
al. 2006).   
 
An additional gene proposed to play a role in low-level isoniazid resistance is kasA.  This 
gene encodes a β-ketoacetyl-ACP synthase, which functions in mycolic acid biosynthesis 
(Mdluli et al. 1998).  Previous studies demonstrated the presence of point mutations in the 
kasA gene in low-level isoniazid resistant isolates (Lee et al. 1999; Piatek et al. 2000).  
However, similar mutations were found in isoniazid susceptible isolates (Lee et al. 1999; 




2.8.2.1. Mode of action 
Rifampicin is a first-line antibiotic (Laurenzo & Mousa 2011) with rapid bactericidal activity 
against M. tuberculosis (Miller et al. 1994).  Together with isoniazid, it forms the backbone 
of first-line anti-TB therapy.  The specific target for rifampicin is the β-subunit (rpoB) of 
prokaryotic RNA polymerase, encoded by rpoB (Miller et al. 1994).  Upon binding of 
rifampicin to rpoB, transcription is physically blocked, leading to inhibition of bacterial 





2.8.2.2. Rifampicin Resistance 
Single step mutations in the rpoB gene are associated with high-level rifampicin resistance 
(Miller et al. 1994).  Previous studies indicate that resistance to rifampicin is rare and occurs 
at a frequency of approximately 10
-8
, approximately 100 times lower than for isoniazid 
(David 1970; Johnson et al. 2006; Bergval et al. 2009).  This low frequency can be attributed 
to mutations in rpoB as the predominant contributor of rifampicin resistance (Tsukamura 
1972).  To date, no alternative mutations associated with rifampicin resistance have been 
identified.  Rifampicin resistance serves as an important indicator for multidrug resistant TB, 
since approximately 90% of rifampicin resistant strains harbour additional resistance to 




2.8.3.1. Mode of action 
Streptomycin is an alternative first-line drug used during retreatment when first-line therapy 
is interrupted (Cooksey et al. 1996).  The target of streptomycin is 16S ribosomal RNA 
(rRNA), which forms part of the 30S small subunit prokaryotic ribosome (Nair et al. 1993; 
Honort & Cole 1994).  Following binding of streptomycin to 16S rRNA, structural ribosomal 
changes are induced (Finken et al. 1993; Sreevatsan et al. 1996), resulting in misreading of 
mRNA during translation and consequently hindering protein synthesis.    
 
2.8.3.2. Streptomycin Resistance 
Resistance to streptomycin is frequently found in M. tuberculosis bacilli harbouring 




respectively (Cooksey et al. 1996; Meier et al. 1996).  More recently, it has been proposed 
that mutations in the gidB gene are associated with low-level streptomycin resistance 
(Okamoto et al. 2007). The gidB gene encodes a SAM-dependent methyltranferase which 
functions in methylation of the bacterial 16S rRNA and thus provides an additional binding 
site for streptomycin.  Mutations within this gene may likely result in termination in 
expression of the methyltransferase enzyme.  Consequently, in the absence of this additional 
binding site, strains harbouring this mutation will acquire streptomycin resistance.  The 
reliability of this gene as a marker for streptomycin resistance is questionable however, since 





2.8.4.1. Mode of action 
Kanamycin is an aminoglycoside which, similar to streptomycin, binds to the 16S rRNA of 
the 30S ribosomal subunit, thereby interrupting protein synthesis (Gikalo et al. 2012).  
Consequently, aminoglycosides are most effective against actively-growing bacilli.  In South 
Africa, kanamycin is the aminoglycoside of choice for the treatment of MDR tuberculosis.     
 
2.8.4.2. Kanamycin Resistance 
Mutations in the rrs gene, which encodes 16S rRNA, are most frequently associated with 
high-level kanamycin resistance (Suzuki et al. 1998).  However, up to 60% of M. tuberculosis 
isolates exhibit low level kanamycin resistance lack mutation in the rrs gene, suggesting 




intracellular survival) promoter has been proposed to play a role in kanamycin resistance 
(Zaunbrecher et al. 2009).  This protein was also shown to encode an aminoglycoside 
acetyltransferase, which acetylates and inactivates kanamycin (Zaunbrecher et al. 2009).  
Initially observed to play a role in intracellular survival in macrophages (Wei et al. 2000), 
this gene was found to be expressed in low-level resistant kanamycin isolates.  So far, the 
aminoglycoside modifying enzymes have not been shown to play a role in the resistance of 




2.8.5.1. Mode of action 
Ofloxacin is a broad-spectrum, early-generation fluoroquinolone (Ginsburg et al. 2003) and 
is, in South Africa, the quinolone of choice for the treatment of MDR tuberculosis.  DNA 
gyrase is responsible for mediating supercoiling of DNA within the bacterial cell 
(Ramaswamy & Musser 1998).  The interaction between ofloxacin and DNA gyrase results in 
double-stranded DNA breakage, preventing supercoiling of DNA (Drlica et al. 2008).  
Although the precise mechanism of killing remains unclear, the DNA gyrase-ofloxacin 
complex is known to physically disrupt DNA replication and gene expression, leading to cell 
death (Kampranis & Maxwell 1998). 
 
2.8.5.2. Ofloxacin Resistance 
Resistance to all quinolones, including ofloxacin, results from mutations in the gyrA gene. 




known to induce resistance-conferring mutations via error-prone DNA repair processes 
(Lopez et al. 2007). 
    
The quinolone resistance determining region (QRDR) in M. tuberculosis comprises gyrA and 
gyrB, which are each directly involved in interaction between DNA gyrase and 
fluoroquinolones (Alangaden et al. 1995).  Missense mutations within gyrA are most 
frequently associated with clinical resistance (Cambaup et al. 1994; Alangaden et al. 1995; 
Kocagöz et al. 1996).  In contrast, gyrB mutations have been predominantly observed in a 
number of resistant laboratory isolates, but are absent in clinical isolates (Kocagöz et al. 
1996; Zhou et al. 2000).  These rare mutations are therefore not frequently associated with 
clinical fluoroquinolone resistance.  The level of fluoroquinolone resistance is dependent on 
the number of mutations acquired within the QRDR (Ouabdesselam et al. 1995).  In contrast 
with single-step mutations conferring high-level rifampicin resistance, high-level 
fluroquinolone resistance only becomes apparent following successive, accumulative 





Table 2.1: Summary of drug targets and resistance-associated genes in M. tuberculosis 
 
















Zhang et al. 1992; 
Banerjee et al. 




Bactericidal RNA  Polymerase 
(Transcripion) 
rpoB Miller et al. 1994 
Streptomycin 
(STR) 
Bactericidal Ribosomal RNA 
(Protein 
synthesis) 
rrs, rpsL, gidB? Nair et al. 1993; 
Finken et al. 1993; 
Okamoto et al. 2007 
Kanamycin 
(KAN) 
Bactericidal Ribosomal RNA 
(Protein 
synthesis) 
rrs, eis? Suzuki et al. 1998; 




Bactericidal DNA gyrase / 
topoisomerase II 
gyrA, gyrB Alangaden et al. 







2.9. Treatment of latent tuberculosis infection 
 
2.9.1. Isoniazid Preventative Therapy 
Soon after the implementation of curative therapy for active disease using antibiotics, it was 
found that isoniazid prevented active disease in guinea pigs (Ferebee & Palmer 1956) and in 
humans (Ferebee et al. 1957).  Isoniazid preventative therapy (IPT) remains the preferred 
treatment for latent tuberculosis, and for the prevention of disease in immunocompromised 
individuals who are at a greater risk of infection (Lobue & Menzies 2010).  More recently, 
recommendations of a combination of isoniazid and rifapentine administered over 3 months 
have been suggested (Sterling et al. 2011).  Prophylactic therapy is not intended to eliminate 
M. tuberculosis, but instead prevents the progression of latent infection to active infection 
(Hawkridge 2007).  As such, during prophylactic therapy, M. tuberculosis growth is 
inhibited.  However, the precise mechanism of activity of isoniazid against M. tuberculosis 
during LTBI remains unclear.   
  
In 1999, Comstock sought to determine the optimal duration of IPT in HIV-infected adults 
(Comstock 1999) based on the findings of two previous studies (Ferebee 1970; Comstock et 
al. 1979).  He established that treatment for at least 10 months resulted in a 68% reduction in 
disease, versus only an 18% reduction for treatment of less than 10 months (Figure 2.7).  
Additionally, there was a steady decrease in the case rate until 9-10 months, after which the 
number of cases remained constant (Comstock 1999).   





Figure 2.7: Comstock's analysis, showing a reduction in TB cases until 9-10 months, 
followed by no further increase or decrease in TB cases. Current IPT recommendations are 
based on this observation.  (Comstock 1999) 
 
 
Comstock’s analysis validates the current recommendation of 9-10 months of IPT.  This 
recommendation, however, is challenged by findings of the Thibela TB Study (Churchyard et 
al. 2014).  In this study, it was found that community-wide use of IPT had no effect in 
controlling TB transmission in gold mines in South Africa by means of mass screening.  
Similarly, in an IPT trial conducted in Botswana (Samandari et al. 2011), resistance to 
isoniazid was observed in 17% of new cases on IPT.  However, the prevalence of resistance 







2.9.2. Drawbacks of IPT for latent infection 
The high prevalence of HIV infection, particularly in sub-Saharan Africa, allows for the 
reactivation of latent infection, or infection with a new strain from a close contact with active 
disease due to a poor immune response in these individuals.  This forms the rationale for the 
use of a 9-month regime of isoniazid prophylaxis in HIV-infected individuals by the World 
Health Organisation (Godfrey-faussett 1998).  Prophylactic therapy is thought not to be 
bactericidal, but instead maintains the bacilli in a dormant state.  However, poor completion 
rates have been reported due to the lengthy duration of treatment (Raviglione et al. 2011).  In 
addition, this 9-month regime has not been favourably received, due to concerns of resistance 
development (Balcells et al. 2006).  Despite this, IPT is still the treatment of choice for LTBI, 
and is particularly recommended in patients with HIV infection that have a positive 
tuberculin skin test (Raviglione et al. 2011). 
 
In theory, IPT can drive resistance in two ways: selection of resistant mutants that develop in 
the patient receiving IPT, and in facilitating preferential spread of resistant strains by 
preventing new infections with susceptible strains.  Of particular concern is the potential for 
acquisition of resistant strains in latently HIV-infected individuals on IPT.  In this regard, IPT 
can be considered a risk factor in the emergence of isoniazid resistance, including isoniazid 
monoresistance, MDR or XDR.   
 
The development of resistance through mutation is thought not to occur during IPT (Ferebee 
1970).   In contrast, by means of mathematical modelling, it was found that the prevention of 
disease during community-wide IPT was followed by an increase in drug resistance (Cohen 




blown active infection and latent infection highlights the fact that selection of resistant 
mutants remains a possibility (Ford & Rubin 2010).   
 
 
2.10. Anaerobic metabolism in Mycobacterium tuberculosis 
 
2.10.1. Association between bacterial growth and oxygen availability 
M. tuberculosis is classically defined as a strict aerobe (Kumar et al. 2011).  As such, it is 
believed to survive exclusively in the presence of oxygen, lacking the ability to survive 
anaerobically.  Conversely, complete genome sequencing of the reference strain H37Rv 
revealed the presence of genes known to play a role in anaerobic metabolism (Cole et al. 
1998).   
 
A key feature of latency is the ability of M. tuberculosis to persist in host granulomas for 
extended periods of time (Flynn & Chan 2001).  Granulomas present hostile conditions to M. 
tuberculosis, including limited oxygen and nutrient availability, acidic pH (Koul et al. 2008) 
and host immune factors including nitric oxide (Kumar et al. 2011)  This suggests that M. 
tuberculosis exhibits a degree of metabolic flexibility, allowing for better adaptation to a 
range of microenvironments within the host.   
 
Oxygen tension and the growth of M. tuberculosis are thought to be closely associated.  In 
humans, the disease rate is higher in coastal regions, where there is a high oxygen tension, 




able to undergo active growth and replication, leading to active disease (Lawn et al. 2011).  
In contrast, the replication rate of M. tuberculosis decreases with reduction in oxygen tension.  
Histological analysis of lung lesions in infected patients revealed high bacterial loads in 
lesions adjacent to open airways with a greater access to oxygen.  The bacterial load and 
number of visible M. tuberculosis bacilli decreased in lesions with restricted access to oxygen 
(Kaplan et al. 2003).  Whether this translates in a reduced rate of active TB disease is 
unknown. 
 
This association with oxygen tension and M. tuberculosis survival may have also formed the 
basis for artificial lung collapse, prior to the introduction of curative therapy using antibiotics. 
Artificial lung collapse was found to be effective in reducing the growth of M. tuberculosis 
due to the reduced accessibility of oxygen to the bacilli (Singer 1936).  However, this method 
led to detrimental consequences (Skinner & Sinclair 1992).   
 
2.10.2. Growth of Mycobacterium tuberculosis under anaerobiosis 
There are several conflicting hypotheses with regards to the replicative state of M. 
tuberculosis under anaerobiosis.  Complete genome sequencing of the control strain H37Rv 
revealed a number of genes known to play a role in anaerobic respiration, including those 
involved in the nitrate respiratory pathway (Cole et al. 1998).  This is affirmed by prior 
studies which showed that fatty acids are utilised as a primary carbon source during latency 
in the absence of oxygen (Segal & Bloch 1956; Gomez & McKinney 2004).  Despite this, M. 





2.11. Latency paradigm 
 
2.11.1. Dormancy of Mycobacterium tuberculosis 
The most widely accepted hypothesis is that the growth of M. tuberculosis is arrested during 
latency.  This is due to the reduced availability of oxygen and nutrients, coupled with 
exposure to acidic pH and host immune effectors including nitric oxide, following granuloma 
formation (Rustad et al. 2008).   
 
2.11.2. The Wayne Model 
The association between oxygen tension and M. tuberculosis growth has prompted the design 
of a number of in vitro hypoxic models representing latent TB infection.  The most widely-
used of these is Wayne’s Hypoxia Model (Wayne & Hayes, 1996).  In this model, tightly-
sealed cultures are allowed to stand unagitated for a period of time.  As the M. tuberculosis 
cells grow and consequently utilise the available oxygen, conditions within the culture flask 
become anaerobic.  Concomitantly, there is significant reduction in metabolic activity within 
the cells as they adapt to oxygen deprived conditions (Wayne & Hayes 1996).  The use of 
methylene blue indicator dye, which decolourises under anaerobic conditions, confirms that 
anaerobiosis is maintained under these conditions (Wayne & Hayes 1996). 
 
Gene expression profiles of M. tuberculosis cultured under the Wayne Model indicate a 
downregulation of genes involved in central metabolic pathways, and an upregulation of 
genes involved in alternate metabolic pathways including fatty acid metabolism  
(Muttucumaru et al. 2004). These bacilli remain susceptible to rifampicin (Mitchison 2004), 




2.11.3. Limitations of dormancy models 
Wayne et al (1996) refer to cells cultured under such conditions as “non-replicating 
persisters” which establish latent infection (Wayne & Hayes, 1996).  While this may support 
the theory that M. tuberculosis growth is inhibited during latency, it fails to explain how 
isoniazid, a drug which targets actively dividing cells, is effective in treating latent infection.  
This raises the question as to whether presumed dormant M. tuberculosis serves as a suitable 
proxy of latent infection in vitro. 
 
Additionally, given the fact that M. tuberculosis retains susceptibility to rifampicin under 
oxygen deprivation, this casts doubt as to whether M. tuberculosis remains dormant under 
anaerobiosis.  Since rifampicin targets RNA polymerase, this indicates that there is a degree 
of metabolic activity under anaerobiosis (Wayne & Hayes, 1996; Wayne & Sramek, 1994).  
This is in contrast with the classical definition of dormancy as a complete metabolic 
shutdown. 
 
2.11.4. Alternative latency paradigm 
While the current paradigm of latent TB infection assumes that the bacteria are in a dormant 
state, there is ample evidence to suggest that M. tuberculosis retains the ability to replicate, 
albeit at a slow rate, during latency.  The two main outcomes of infection with M. 
tuberculosis are either active infection leading to active disease if uncontrolled, or latent 
infection.  These two outcomes are presumed to be mutually exclusive, with bacilli 
comprising each outcome exhibiting distinct metabolic and replicative profiles.  
Retrospective analyses, however, suggests that this concept may significantly simplify the 




Zumla et al. 2011).   A recent study revealed overlap in the host transcriptional response to 
active and latent infection.  The expression profile of such genes is thought to distinct 
between the two disease states (Fortune & Rubin 2010).  This suggests that active infection 
and latent infection may not be distinct entities. 
 
Furthermore, isoniazid is bactericidal against actively dividing bacilli, yet is effective in 
preventing disease reactivation in latently infected individuals.  It is therefore likely that 
during latency, the pool of bacilli alternate between spurts of metabolic activity and 
dormancy (Lawn et al. 2011).  Latent tuberculosis can thus be viewed as subclinical infection 




2.12. Mutational capacity of Mycobacterium tuberculosis during latent 
infection 
Clinical observations and classic dormancy models suggest that M. tuberculosis lacks the 
ability to grow during latent infection.  This assumption forms the basis for the current 
treatment of latent tuberculosis infection with prophylactic therapy using a single drug 
(Sterling 2008).  Multidrug therapy is thought to be inessential during latent infection, since 
the bacilli are presumed to lie dormant and as such, do not mutate.   
 
Challenging this concept, a recent study provided evidence that M. tuberculosis does retain 




cynomolgus macaques were infected with M. tuberculosis, and bacilli isolated from lesions at 
three distinct disease states: active lesions, latent lesions and reactivated lesions.  Whole 
genome sequencing revealed a higher number of resistance conferring mutations in those 
bacteria isolated from latent and reactivated lesions than those isolated from active lesions 
(Ford et al. 2011).  These findings are in stark contrast with current latent TB models, in 
which the bacteria are presumed to lay dormant due to a cessation of replication, and hence 
acquire few to no mutations. 
   
One of the contributors to the high mutation acquisition during latency could be the 
accumulation of reactive oxidative species, capable of directly inducing DNA damage.  
Consistent with this, ten of the fourteen mutations identified were products of oxidative 
damage, either due to cytosine deamination or 8-oxoguanine formation (Ford et al. 2011).  
This is thought to occur due to exposure to these oxidative intermediates within the 
granuloma in vivo.  Since latency manifests as long-term infection, the duration of exposure 
to these reactive intermediates increases, resulting in further DNA damage (Ford et al. 2011).  
Additionally, reduced replication rates during latency may be accompanied by a 
downregulation in DNA repair (Ford et al. 2011).   This could contribute to the high mutation 






Figure 2.8: Alternative model for mutation acquisition in M. tuberculosis during latency 
(Ford et al. 2011) 
 
Based on the ability of M. tuberculosis to survive and metabolise anaerobically (Ramchandra 
& Sturm 2010), it is possible that reactive nitrogen species produced during anaerobic 
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Background:  Infection with Mycobacterium tuberculosis results in either active disease or 
latent infection.  The two predominant M. tuberculosis strain families circulating in 
KwaZulu-Natal are F15/LAM4/KZN and Beijing.  Drug resistance is defined on the basis of 
mutation acquisition.  M. tuberculosis is thought to lie dormant and acquire few to no 
mutations during the course of latent infection.  In contrast, recent evidence suggests that M. 
tuberculosis may retain the ability to mutate during latent infection.  
Methods:  Using the Luria-Delbrück fluctuation analysis, the frequency of resistance-
conferring mutations in isolates of M. tuberculosis was determined.  Two susceptible isolates 
of each strain family and H37Rv were used. Low-density cultures of each isolate were grown 
under aerobic and anaerobic conditions.  Resistance acquisition frequency to isoniazid 
(1µg/ml), rifampicin (1µg/ml), streptomycin (2µg/ml), ofloxacin (2µg/ml) and kanamycin 
(5µg/ml) was expressed as the proportion of resistant CFU/ml to the total CFU/ml. This was 
used as a proxy for mutation frequency. 
Results:  Aerobically, F15/LAM4/KZN isolates acquired resistance at higher frequencies 
than the Beijing isolates and H37Rv against rifampicin, streptomycin and kanamycin 
(P<0.0001).  The mutation frequencies for these drugs were similar or higher than for 
isoniazid.  No differences were observed with isoniazid or ofloxacin between the isolates 
(P>0.05). Under anaerobic conditions, the KZN isolates were found to acquire resistance at 
higher frequencies than the Beijing isolates (P<0.0001).  
Conclusions:  F15/LAM4/KZN isolates acquired resistance at higher frequencies under 
aerobic and anaerobic conditions as compared to Beijing isolates.  This suggests a 






Drug resistance in Mycobacterium tuberculosis has reached proportions threatening the 
success of current TB control programs. Multidrug-resistant (MDR) organisms are resistant 
to isoniazid and rifampicin, while extensively drug-resistant (XDR) organisms have acquired 
additional resistance to fluoroquinolones and any of the second-line injectables 
(capreomycin, amikacin or kanamycin) (Ioerger et al. 2009).  More recently, totally drug-
resistant isolates have been reported from Italy (Migliori et al. 2007), Iran (Velayati et al. 
2009), India (Udwadia et al. 2012) and most recently, South Africa (Klopper et al. 2013).   
 
The development and emergence of drug resistance is determined by bacterial factors, mainly 
mutation acquisition, and host factors such as non-adherence to treatment.  Its cell wall 
structure makes horizontal gene transfer in M. tuberculosis unlikely (Pillay & Sturm 2007) 
and there exists little evidence that M. tuberculosis contains plasmids (Ramaswamy & 
Musser 1998). Therefore, drug resistance in this speciesis considered to arise mainly via 
spontaneous mutations (Gillespie 2002).  Measurement of the fraction of resistant colony 
forming units for a specific antimycobacterial agent in a population of bacteria can thus be 
used as a proxy for mutation frequency.   
 
A recent study by Moodley et al (2011) indicates the high prevalence of MDR and XDR 
tuberculosis within the KwaZulu-Natal province of South Africa (Moodley et al. 2011).  
Strains associated with resistance within this province are the Beijing and the 




between strains.  Due to the widespread distribution of the Beijing strain, it is considered to 
be the most successful family of strains of M. tuberculosis globally (Glynn et al. 2002; 
Hanekom et al. 2011), and is epidemiologically associated with multidrug-resistance (Brown 
et al. 2010; de Steenwinkel et al. 2012).  It is therefore presumed to acquire mutations at a 
higher frequency during the course of infection than other strains.  In KwaZulu-Natal 
however, the KZN strain shows a high association with drug resistance.  This family of 
strains has developed from multidrug-resistance to extensive drug-resistance within a decade 
(Pillay & Sturm 2007).  This suggests that both the KZN and Beijing strains acquire 
resistance-conferring mutations at high frequencies. 
 
Infection with M. tuberculosis results in either active disease or latent infection.  Each is 
characterised by the presence of bacteria with vastly different and distinct replicative and 
metabolic profiles.  During latent tuberculosis infection (LTBI), M. tuberculosis bacilli enter 
a state of presumed dormancy, characterised by arrested growth and hypometabolism (Loebel 
et al. 1933; Wayne & Hayes 1996). LTBI poses a major obstacle in the control of 
tuberculosis, as it serves as a potential reservoir for future spread of the disease (Parrish et al. 
1998).   
 
During LTBI, M. tuberculosis is phagocytosed and driven into a quiescent state by host 
alveolar macrophages to form granulomas (Flynn & Chan 2001).  Within the granuloma, M. 
tuberculosis is proposed to be exposed to a range of hostile conditions including limited 
oxygen and nutrient availability (Wayne 1994), acidity and pH (Tan et al. 2010), each of 
which are non-conducive to active growth. In lung lesions the number of visible M. 




Following this, in vitro dormancy models use anaerobiosis as a proxy for latent infection. In 
vitro dormancy models suggest a state of non-replicating persistence characterised by a 
metabolic shutdown (Wayne 1994).   However, this fails to explain how drugs like isoniazid, 
which targets actively dividing cells, is effective against latent infection.   
 
Challenging common dormancy models, recent evidence suggests that M. tuberculosis 
remains metabolically active, and possibly replicates, during latency (Barry  3rd et al. 2009; 
Chao & Rubin 2010; Lawn et al. 2011).  This suggests that the two outcomes of M. 
tuberculosis infection, active disease and latent infection, are not mutually exclusive.  
Instead, latent infection may comprise a spectrum of bacilli with a range of metabolic 
activities. This is supported by a recent study (Ford et al. 2011) in which M. tuberculosis 
isolated from latent lesions in macaques was shown to have acquired resistance-conferring 
mutations at a higher rate than those isolated from active lesions.   This raises the question as 
to whether M. tuberculosis retains the capacity to acquire resistance during anaerobic 
metabolism, possibly reflecting latency.  
 
We sought to compare the mutation frequencies in the genes coding for the MDR and XDR 
defining drug targets between isolates from the Beijing and KZN families, under aerobic and 
anaerobic conditions.  Anaerobic incubation is used as a proxy for latency, and frequency of 





MATERIALS AND METHODS 
 
Bacterial strains 
Two clinical isolates of the Beijing family and two of the KZN family were used as well as 
reference strain H37Rv.  All isolates were susceptible to all drugs tested, and was defined as 
no growth on Middlebrook 7H10 agar containing the following drugs: isoniazid (1 µg/ml), 
rifampicin (1 µg/ml), streptomycin (2 µg/ml), kanamycin (5 µg/ml) or ofloxacin (2 µg/ml).  
 
Fluctuation analysis 
One hundred L of frozen M. tuberculosis suspension of each isolate was inoculated in 
enriched 7H9 broth containing 10% OADC, 0.5% glycerol and 0.05% Tween-80 and 
incubated at 37
o
C until an OD600nm of 1 was reached.  This was used to prepare low-density 
cultures.   
For the aerobic assays, 100 µL of culture was inoculated into 10mL of enriched 7H9 broth.  
Five hundred µL of this diluted culture was then inoculated into 100mL of 7H9 broth, to 
yield a final dilution of 1/20,000.  Aliquots of 4mL of this diluted culture were then dispensed 
into 20 inkwell bottles.  For the aerobic assays, these cultures were incubated at 37
o
C in a 
shaking incubator until an OD600nm of 1, corresponding to the end of log phase, was obtained.  
For the anaerobic assays, the same process was followed.  Once an OD600nm of 1 was reached 
in each of the initial cultures, they were transferred to a Forma Anaerobic Chamber.  The 
remaining steps to prepare the 1/20,000 diluted cultures were performed within the Anaerobic 
Chamber, using prereduced 7H9 broth. The twenty 4 mL aliquots of each isolate were 
incubated anaerobically within the chamber at 37
o




took between 6 and 8 weeks.  Anaerobic conditions were confirmed using Bacteroides 
fragilis ATCC 25285 and a resazurin indicator strip (Oxoid). 
Once the OD600nm reached 1 in both the aerobically and anaerobically incubated cultures, the 
entire culture from each of the 20 inkwell bottles was sonicated for 10 seconds each at an 
amplitude of 15 Hz using the Misonix 4000 Ultrasonic Liquid Processor. Six tenfold dilutions 
of each of the 20 sonicated cultures were prepared in PBS supplemented with 20% Tween.  
Of each dilution, 200 µL aliquots were plated onto each of two drug-free Middlebrook 7H10 
plates.   
The remaining 3900 µL of each culture was centrifuged at 4000 r.p.m. for 10 minutes at 
25
o
C.  The supernatant was decanted and the pellets were resuspended in 200 µL of 7H9 
broth and homogenised by vortexing.  The entire volume of each of the 20 resuspended 
pellets was plated onto five Middlebrook 7H10 plates containing isoniazid (1µg/mL), 
rifampicin (1µg/mL), streptomycin (2µg/mL), ofloxacin (2µg/mL) and kanamycin (5µg/mL) 
respectively.  A drug-free plate was included as a control, in order to demonstrate that the 
drug-containing plates permitted growth of mutants only, and that growth on the drug-
containing plates was not a result of inactivity of the drugs.   Plates were incubated at 37
o
C in 
5% CO2 for 32 days and the number of resistant colonies as well as the total number was 
counted for each of the 20 cultures. Resistant and total colony counts obtained from each of 
the 20 identical cultures were averaged.  Select resistant colonies were verified to be acid-fast 
bacilli by means of the Ziehl-Neelsen stain. 
For each isolate, the proportion of resistant colonies of the total colony count against each 
drug was determined.  The proportion of resistant colonies was taken as a proxy for the 






GraphPad InStat 3.00 was used.  The Kruskal-wallis Test (Non-parametric ANOVA) with 
Dunn’s Multiple Comparisons Test was applied for all statistical analyses.  P values < 0.05 
were considered significant.     
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Table 1 shows the number of resistant mutant CFUs in a total population of 10
6
 bacilli under 
aerobic and anaerobic conditions.   
 
There was no significant difference between the frequency of mutation acquisition conferring 
isoniazid resistance between the KZN and Beijing isolates, and H37Rv (P>0.05) under 
aerobic conditions.  Both Beijing isolates and H37Rv acquired resistance to isoniazid at the 
highest frequency as compared to the other drugs.  The KZN isolates acquired resistance to 
isoniazid at similar rates to rifampicin (P=0.4772) and kanamycin (P=0.3317).  These isolates 
acquired resistance to streptomycin at significantly higher frequencies than to isoniazid 
(P<0.0001).  The KZN isolates acquired resistance at higher frequencies than those of the 
Beijing family and H37Rv for rifampicin (P<0.0001), streptomycin (P<0.0001) and 
kanamycin (P<0.0001 for the Beijing isolates and P = 0.008 for H37Rv).  There was no 
significant difference in mutation frequencies conferring ofloxacin resistance between 
isolates and H37Rv (P>0.05).  
 
All four clinical isolates as well as H37Rv survived the sudden change from aerobic to 
anaerobic incubation conditions. All grew well anaerobically, although at a slower rate than 
aerobically. Both KZN isolates acquired resistance to isoniazid (P<0.0002), rifampicin 
(P<0.0005), streptomycin (P<0.0001), kanamycin (P<0.0001) and ofloxacin (P<0.0004) at 







Fluctuation analysis protocols use low density inocula. This ensures that no pre-existing 
mutants are present in the inoculum prior to incubation, and that a sufficient number of 
multiplication rounds can occur before the end of the log phase is reached.  This allows for 
the measurement of spontaneously-occurring mutations during the incubation period.  
 
Isolates of the KZN family acquired resistance to rifampicin, streptomycin and kanamycin 
more frequently than the Beijing isolates and at frequencies comparable to isoniazid 
resistance.  This implies that strains belonging to the KZN family do have an enhanced 
capacity to acquire drug resistance compared to those of the Beijing family. Only two 
susceptible isolates belonging to each strain family were used in this study, since our M. 
tuberculosis collection contains only two confirmed susceptible isolates belonging to the 
KZN strain family. 
 
The Beijing isolates and H37Rv acquired rifampicin resistance conferring mutations at an 
approximately 100-fold lower rate than to isoniazid.  This is in accordance with most studies 
(David 1970; Johnson et al. 2006; Bergval et al. 2009).  However, both the KZN isolates 
acquired rifampicin resistance at a much higher frequency than those belonging to the Beijing 
family and H37Rv.  In the KZN isolates, the mutation frequency for rifampicin was similar to 
that for isoniazid.  This suggests that the KZN strain needed shorter exposure to inadequate 





The mutation frequencies conferring streptomycin resistance in both KZN isolates were 
approximately 100 fold higher than that of the Beijing strains. The multidrug-resistant KZN 
variant, from which the first extensively drug-resistant strain developed, revealed early 
resistance to streptomycin (Pillay & Sturm 2007).  Until recently, TB treatment protocols in 
South Africa included the addition of streptomycin to first line drugs in case of treatment 
failure before susceptibility tests become available (South African Department of Health 
2004), which undoubtedly has added to the resistance selection. 
 
All isolates acquired isoniazid resistance at comparably high frequencies.  These high 
mutation frequencies are in accordance with the number of isoniazid resistance associated 
genes (Johnson et al. 2006).  The true mutation frequency may even be higher since the 
design of the study did not allow the detection of mutations in the inhA gene.  Isoniazid is 
used singly as a prophylactic drug to prevent disease reactivation in latently infected HIV-
infected individuals (Raviglione et al. 2011).  Given the high mutation frequencies to 
isoniazid for all strains, the importance of excluding active TB infection prior to 
administering isoniazid prophylaxis (Reddy et al. 2010) is emphasized. 
 
There was no difference observed in mutation frequencies conferring ofloxacin resistance for 
the KZN and Beijing isolates.   All strains acquired ofloxacin resistance at the lowest 
frequencies.  This may be explained by the fact that high-level fluoroquinolone resistance is 
observed after stepwise acquisition of mutations in the gyrA gene, and not via single 
mutational events (Ginsburg et al. 2003).  Therefore, the methodology applied here may not 





Data pertaining to differences in the mutation rates in different strain families is conflicting.  
One group (Werngren & Hoffner 2003) reported similar mutation rates in the Beijing family 
as non-Beijing strains.  In contrast, others (de Steenwinkel et al. 2012; Ford et al. 2013) 
showed that Beijing strains acquired rifampicin resistance at significantly higher rates than 
non-Beijing strains.  We report significant differences between the KZN and Beijing strain 
families.   
   
The reported association of the Beijing family with drug resistance may not necessarily be as 
a result of its mutational capacity, but instead reflect the high number of people infected with 
this strain, providing a larger bacterial population that can potentially mutate.  This is 
supported by the observations of Werngren and Hoffner (2003) (Werngren & Hoffner 2003).  
The high mutational capacity of the KZN strains could be a result of a higher replication rate, 
leading to a greater possibility of replicative error due to error-prone DNA polymerase 
(Boshoff et al. 2003), resulting in a higher mutation frequency.  However, the Beijing strains 
were observed to grow faster in 7H9 broth than the KZN strains.  Therefore, a more likely 
possibility is that the KZN family exhibit a mutator phenotype. Mutations have been 
identified in the DNA repair genes mutT2 and mutT4 in Beijing strains (Ebrahimi-Rad et al. 
2003; Lari et al. 2006). 
 
Mutation frequencies leading to drug resistance are thought to differ between strain families 
(Brown et al. 2010; Ford et al. 2013).  The KZN isolates acquired significantly more 
mutations conferring resistance to all drugs tested than the Beijing isolates under anaerobic 




frequently than Beijing strains under aerobic conditions, possibly reflecting defective DNA 
repair systems within the KZN family.  
 
The mutational capacity of M. tuberculosis forms the basis for treatment regimens with 
multiple drugs, in order to prevent the selection of resistant mutants during treatment. Active 
TB infection is treated by a combination of drugs, since during this manifestation of disease, 
M. tuberculosis is presumed to undergo active replication and consequently accumulates a 
number of mutations.  In contrast, the rationale to use single drug treatment to prevent 
reactivation disease is based on previous observations that M. tuberculosis lacks the ability to 
replicate and acquire mutations during the course of latent infection.  Using anaerobiosis as a 
proxy for latent infection in vitro, the results of this study indicate that M. tuberculosis does 
retain the ability to multiply, albeit at a slow rate, and consequently acquire mutations 
anaerobically. As shown in Table 1, clinical M. tuberculosis isolates of the Beijing and KZN 
families, and H37Rv, each acquire resistance at mostly similar or higher frequencies under 
anaerobic conditions than aerobic conditions.  This is in support of the study by Ford et al 
(2011), which shows that M. tuberculosis isolated from latent lesions in macaques with M. 
tuberculosis infection, acquire mutations leading to resistance at a higher rate than those 
isolated from active lesions (Ford et al. 2011). 
 
Factors which may contribute to mutation acquisition include downregulation in DNA repair, 
accompanying the reduction in bacterial replication under anaerobic conditions (Ford et al. 
2011).  An alternative source of DNA damage leading to mutation acquisition anaerobically 
are reactive nitrogen species (Kumar et al. 2011).  Prolonged incubation in broth under 




nitrogen species, a by-product of anaerobic metabolism.  This could increase the rate of DNA 
damage, leading to resistance if damage occurs in genes coding for drug targets.  This is 
supported by the study by Ford et al (2011), which showed that ten out of fourteen mutations 
observed in latent lesions were as a result of oxidative damage (Ford et al. 2011).    
 
The current latency paradigm indicates little to no replication (Wayne, 1994), negating the 
possibility of mutation acquisition leading to resistance during the course of infection.  This 
forms the basis for isoniazid preventive therapy (IPT). However, the results presented here 
indicate that M. tuberculosis retains the ability to mutate in vitro under anaerobic conditions.  
If anaerobic conditions reflect latent infection, then IPT may result in the generation of de 
novo isoniazid resistance. 
 
In conclusion, the adaptation of M. tuberculosis to anaerobic conditions in vitro offers a 
simplified representation of the environment faced by the bacterium as it establishes latent 
infection.  Although the true role of anaerobic multiplication in latent infection remains to be 
elucidated, an anaerobic environment does exit in the human host and the slower replication 
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Table 1:  Resistance-conferring mutations acquired in a population 10
6
 bacilli under aerobic and anaerobic conditions 
 Beijing F15/LAM4/KZN   
 
TF1516 TF2284 V9124 V4207 H37Rv 
O2 AnO2 O2 AnO2 O2 AnO2 O2 AnO2 O2 AnO2 
INH
1
 15 5.03 9.3 1.08 8.4 14.2 2.24 32.75 7.4 35.8 
RIF
2
 0.29 0.573 0.118 0.761 5.8 2.38 3.68 5.76 0.36 1.95 
STR
3
 0.12 0.2025 0.2 0.212 11 196 14.4 189.8 1.89 11.5 
KAN
4
 0.33 1.95 2.5 0.588 6.9 22.7 6.65 13.2 1.79 9.32 
OFX
5
 0.49 0.139 0.079 0.317 2.1 0.339 0.94 1.43 0.475 14.9 
O2 = Aerobic; AnO2 = Anaerobic 




Isoniazid resistance was acquired at similar frequencies for TF1516 (P=0.0851), TF2284 (P=0.5073) and H37Rv (P<0.0001) under aerobic and anaerobic 
conditions.  Isoniazid resistance was acquired at significantly higher frequencies for V4207 (P = 0.0473) and H37Rv (P<0.0001) under anaerobic conditions.  
 
2
 TF1516 acquired rifampicin resistance at a similar frequency under aerobic and anaerobic conditions (P = 0.9892).  V9124 acquired rifampicin resistance at 
a lower frequency anaerobically (P=0.0351). TF2284, V4207 and H37Rv each acquired rifampicin resistance at significantly higher frequencies under 
anaerobic conditions (P<0.05). 
 
3
 Both of the Beijing isolates acquired streptomycin resistance at similar frequencies under aerobic and anaerobic conditions (P>0.05).  Streptomycin 
resistance was acquired at higher frequencies for each of the KZN isolates (P<0.0001) and H37Rv (P = 0.0084) under anaerobic conditions. 
 
4
 TF1516 was found to acquire kanamycin resistance at a similar frequency under aerobic and anaerobic conditions (P = 0.5941), while TF2284 acquired 
kanamycin resistance at a lower frequency anaerobically (P<0.05).  Each of the KZN isolates and H37Rv acquired kanamycin resistance at significantly 
higher frequencies anaerobically (P<0.005).   
 
5
 TF1516, V4207 and H37Rv acquired ofloxacin resistance at significantly higher frequencies anaerobically (P<0.05).  Ofloxacin resistance was acquired at 




CHAPTER 4: DISCUSSION 
 
4.1. Mutation acquisition under aerobic conditions 
The findings presented in this dissertation support epidemiological association of the Beijing 
strain with multidrug resistance (MDR), and the KZN strain with extensive drug resistance 
(XDR).  Given the high frequencies of resistance acquisition of the KZN strain, we provide 
an explanation for the overrepresention of this strain in patients with XDR-TB in KwaZulu-
Natal. 
 
4.2. Mutation acquisition under anaerobic conditions 
The classical definition of M. tuberculosis dormancy is a cessation of bacterial replication 
accompanied by complete metabolic shutdown (Wayne 1994; Wayne & Sohaskey 2001). 
Dormancy is the state the bacteria are in while the term latency refers to the state of the 
disease. However, “dormancy” is a much disputed term in “latency” (Chao & Rubin 2010).  
We used the Hypoxia Model to imitate conditions encountered by M. tuberculosis within the 
granuloma during latency.  In contrast with the Wayne Model (Wayne & Hayes 1996), we 
immediately exposed the cultures to anaerobic conditions. 
 
Table 1 shows that M. tuberculosis retains the ability to acquire resistance-conferring 
mutations at either similar or higher frequencies under anaerobic conditions as compared to 




If anaerobic conditions are a proxy for latent infection, then the mutation frequencies of M. 
tuberculosis is at least higher as in acute infection. 
 
4.3. Antibiotic-mediated mutation acquisition 
Exposure to bactericidal antibiotics is known to stimulate ROS production via the generation 
of hydroxyl radicals (OH·), subsequently inducing mutations (Kohanski et al. 2007).  In 
contrast, exposure to bacteriostatic drugs does not lead to the production of OH·.    Since all 
five antimicrobial agents used are bactericidal (Table 2.1), increase in the mutation frequency 
on exposure after plating is possible.  Differences in resistance development between drugs 
may be related to differences in mutation induction by these compounds. 
 
4.4. Technical considerations 
4.4.1. Clumping 
Estimation of mutation frequencies relies extensively on accurate colony counts following 
incubation on agar.  M. tuberculosis is known to clump during replication as a result of its 
cording factor (Darzins & Fahr 1956), and this may greatly hamper accurate colony counts.  
In order to control for clumping, all cultures were incubated in 7H9 broth containing 0.05% 
Tween-80, a detergent known to reduce clumping (Jacobs et al. 1991).  Following incubation 
in broth under both aerobic and anaerobic growth conditions, all cultures were sonicated to 
further disperse clumps.  Prior to plating of both the diluted cultures onto drug-free 7H10 
agar, and resuspended pellets onto drug-containing 7H10 agar, cultures were briefly vortexed 




Suspensions from select cultures were stained via the Ziehl-Neelsen method and viewed 
microscopically to determine whether cultures were free of contaminating bacteria.  
Microscopic observation revealed that the development of clumps during incubation with 
Tween-80 were minimal. 
 
4.4.2. Confirmation of resistance 
Following incubation on antibiotic-containing 7H10 agar, select resistant mutant colonies 
were picked and used to prepare a 1 MacFarland suspension for susceptibility testing using 
the absolute proportion method.  All pick-offs were tested for all five drugs.  Monoresistance 
solely to the antibiotic used for selection was observed, confirming phenotypic resistance for 
the relevant antibiotic.  In addition, this supports prior observations that resistance is not 
acquired to more than one drug simultaneously.  
 
4.5. Limitations 
Only two susceptible isolates belonging to each strain family were used in this study, since 
our M. tuberculosis collection contains only two confirmed susceptible KZN isolates.  Based 
on this, we cannot draw a specific conclusion on strain-dependent resistance development.  
These observations could be strengthened by including representative strains belonging to 
different families.  However, our results do support the existing association of the KZN 





Mutation acquisition leading to resistance was defined by the appearance of growth on 
antibiotic-containing agar.  While these resistance-conferring mutations were confirmed 
phenotypically via susceptibility testing, sequencing to determine the presence of resistance-
associated mutations in the genes coding for the drug targets would have provided additional, 
genetic confirmation of resistance.  However, this would have increased the body of work 
beyond that of a Masters degree project. 
 
4.6. Conclusions 
Mutation acquisition between strain families may vary under both aerobic and anaerobic 
growth conditions.  M. tuberculosis retains the ability to acquire mutations leading to 
resistance under both aerobic and anaerobic growth conditions. 
 
4.6.1. Suggestions for further research 
This study focussed on phenotypic resistance only.  Sequencing of the whole genome, or 
previously defined resistance-associated genes, in spontaneously-generated mutants would 
allow the identification of potential alternative resistance mechanisms or associated genes.  
Given the high mutational capacity of the KZN family, genes known to encode DNA repair 
machinery should be sequenced in order to identify mutations contributing to defective DNA 
repair activity.  Sequencing of genes encoding products known to repair oxidative damage 





Finally, gene expression could be performed on aerobically and anaerobically incubated 
cultures in order to establish whether DNA repair genes are upregulated or downregulated 
under oxygen deprivation.  This could serve as an indication of the mutational capacity of M. 
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Appendix A: Drug stocks 
 
Antibiotic Diluent Final concentration 
Isoniazid Distilled water 1 µg/ml 
Rifampicin 30% methanol 1 µg/ml 
Streptomycin Distilled water 2 µg/ml 
Ofloxacin Distilled water 2 µg/ml 














Appendix B: Culture media 
 
7H9 broth 
4.7g 7H9 powder was dissolved in 900ml distilled water containing 2ml glycerol and 
autoclaved for 15 minutes at 121
o
C.  After autoclaving, the media was cooled down to 55
o
C 
and supplemented with 100ml OADC and 1.25ml 20% tween (to prevent clumping).  In order 
to confirm sterility prior to use, two drops of the media was inoculated onto a blood agar 
plate and incubated overnight.   
7H10 agar (Non-selective media) 
38g of 7H10 powder was dissolved in 1800ml distilled water in a 3-litre flask containing10ml 
glycerol and 2g casitone.  The media was autoclaved for 15 minutes at 121
o
C.  After 
autoclaving, the media was placed in a water bath and cooled to 55
o
C.  After cooling, the 
media was supplemented with 200ml OADC and rapidly poured into 90mm plates.  Each 
plate received 20-22ml agar.  Once the media had cooled and solidified, sterility was 
confirmed by placing one plate in a CO2 incubator overnight.  These plates were used to 
obtain the total CFU count.   
7H10 agar (Selective media) 
7H10 agar was prepared as described above.  After autoclaving, the agar was placed in a 
water bath and cooled to 45
o
C.  At this temperature, the agar was then supplemented with 
200ml OADC and 2ml of antibiotic (either isoniazid, rifampicin, streptomycin, ofloxacin or 
kanamycin), and rapidly poured into 150mm plates.  Each plate received 90ml agar.  Sterility 






Appendix C: Confirmatory Tests 
 
Ziehl-Neelsen staining 
1. 1-2 drops of suspensions of culture presumed to be M. tuberculosis were placed onto 
fresh slides.   
2. The slides were heat-fixed on a hot plate at 65˚C under UV light for 1 hour.  This also 
permitted the heat-killing ofM. tuberculosis.   
3. The fixed slides were then flooded with carbol fuchsin dye and heated gently, in order 
to allow the dye to enter all the bacterial cells.  The slides were then rinsed. 
4. The slides were decolourised with 3% acid alcohol for 1 minute and rinsed. 
5. The slides were counterstained with methylene blue for 1-2 minutes and rinsed. 
6. All slides were allowed to air-dry. 
7. Stained slides were viewed under a light microscope at 100x magnification to confirm 
the presence of M. tuberculosis, the absence of contamination, and to directly confirm 











Drug susceptibility testing 
1. Single colonies were inoculated into 4ml tween buffer with beads and vortexed for 1-
2 minutes.  Dense particles were allowed to settle. 
2. These suspensions were adjusted to a No. 1 McFarland standard using distilled water 
and vortexed.  
3. Each of the suspensions was then serially diluted by inoculating 500 µl of the no.1 
McFarland to 4.5ml distilled water, vortexing until a dilution of 10
-4
 was reached. 
4. The control (drug-free) and drug-containing quadrants were each inoculated with 3 
drops of the 10
-4
 dilution, and the plates gently tilted to spread inoculum 
5. The plates were allowed to dry in the biosafety cabinet and then packed into CO2 
permeable plastic packets, and incubated at 37
o
C for 3 weeks 
6. Strains were only defined as susceptible strictly in the absence of colonies on the 





Appendix D: Colony Counts 
 
TF1516: AEROBIC                   
                     
Resistant CFU counts                   
                     
INH 84 111 142 173 163 0 217 0 4 190 35 0 45 0 512 1 252 304 126 398 
RIF 2 0 1 3 8 12 1 32 12 3 15 27 11 12 5 4 18 7 4 8 
OFX 4 12 5 9 22 9 2 21 13 22 24 5 47 23 11 16 12 11 28 3 
STR 4 22 7 9 43 5 17 10 9 15 8 10 4 19 20 10 18 8 21 7 
KAN 49 34 30 42 36 2 0 48 14 17 22 16 47 142 39 44 13 33 26 29 
                     
                     
Mutation Frequencies                   
                     
Drug 
Resistant 
CFU/ml Total CFU/ml 
Mutation 

































TF1516: ANAEROBIC                   
                     
Resistant CFU Counts                   
                     
INH 253 4 301 0 387 52 100 46 143 10 9 108 0 2 78 1 291 1 53 0 
RIF 4 32 14 2 1 0 0 2 15 2 6 0 0 1 0 4 0 8 1 9 
STR 1 3 10 1 3 2 0 0 1 0 1 0 2 0 0 1 2 1 1 4 
OFX 0 3 3 1 0 0 0 3 0 1 1 1 0 0 0 0 4 3 0 4 
KAN 3 4 0 5 45 0 44 2 0 7 0 5 0 0 0 1 0 76 0 0 
                     
                     
                     
Mutation Frequencies                   
                     
Drug 
Resistant 
CFU/ml Total CFU/ml 
Mutation 































TF2284: AEROBIC                   
                     
Resistant CFU Counts                   
                     
INH 0 156 135 0 140 171 68 122 120 95 114 115 31 720 224 278 401 126 98 86 
RIF 3 9 5 0 6 2 3 2 4 1 1 3 2 3 2 4 7 4 1 2 
OFX 2 4 3 3 13 20 16 57 7 5 10 2 0 6 5 0 1 22 3 0 
STR 0 28 8 4 9 11 6 11 3 16 8 21 198 17 11 5 4 8 9 3 
KAN 0 209 126 138 114 165 188 208 140 104 124 198 150 312 106 166 142 0 132 152 
                     
                     
Mutation Frequencies                   
                     
Drug 
Resistant 
CFU/ml Total CFU/ml 
Mutation 































TF2284: ANAEROBIC                   
                     
Resistant CFU Counts                   
                     
INH 119 63 29 31 27 66 87 129 60 100 62 13 71 102 104 7 0 87 153 0 
RIF 5 0 0 10 0 2 6 8 0 2 1 3 8 2 2 16 2 2 1 0 
STR 4 14 12 5 12 1 1 8 114 1 15 0 31 2 1 1 6 4 25 60 
OFX 4 0 1 3 0 1 11 0 2 55 1 0 0 0 2 0 1 0 1 2 
KAN 0 0 0 0 0 86 12 0 0 62 169 2 154 139 0 0 221 0 18 21 
                     
                     
Mutation Frequencies                   
                     
Drug 
Resistant 
CFU/ml Total CFU/ml 
Mutation 































V9124: AEROBIC                   
                     
Resistant CFU Counts                   
                     
INH 154 140 284 1180 1280 908 265 283 293 272 281 406 198 340 256 72 0 64 498 267 
RIF 33 16 11 0 104 8 44 39 118 232 0 360 116 238 46 39 3 23 9 37 
OFX 3 7 5 3 1 5 9 15 1 32 7 23 2 18 2 1 3 4 17 393 
STR 24 7 131 160 51 86 36 137 49 24 46 187 160 93 130 244 346 230 402 535 
KAN 13 27 6 6 4 212 52 14 564 1 25 11 17 10 185 36 114 27 5 374 
                     
                     
Mutation Frequencies                   
                     
Drug 
Resistant 
CFU/ml Total CFU/ml 
Mutation 































V9124: ANAEROBIC                   
                     
Resistant CFU Counts                   
                     
INH 465 10 137 62 210 190 216 149 0 45 110 0 487 169 79 14 8 59 30 18 
RIF 2 35 63 60 0 1 5 37 0 55 5 0 10 0 1 35 0 0 0 1 
STR 79 290 124 84 126 201 115 34 206 82 93 345 87 198 129 256 139 267 24 38 
OFX 2 0 1 2 1 14 2 1 1 1 2 3 6 3 0 0 2 3 4 1 
KAN 0 158 133 152 107 60 75 56 108 82 104 176 87 84 127 67 85 125 117 5 
                     
                     
Mutation Frequencies                   
                     
Drug 
Resistant 
CFU/ml Total CFU/ml 
Mutation 































V4207: AEROBIC                   
                     
Resistant CFU Counts                   
                     
INH 219 213 220 318 339 270 492 394 195 261 153 205 489 178 209 152 220 227 96 650 
RIF 44 31 174 46 3 15 1 2 11 8 99 57 98 69 1 39 52 36 86 55 
OFX 1 1 1 2 0 2 1 0 1 4 1 1 0 3 2 3 2 0 13 4 
STR 119 256 228 73 272 153 418 174 260 142 171 442 127 94 128 0 151 128 168 145 
KAN 136 104 168 142 80 101 185 120 97 65 0 61 146 35 70 88 124 71 124 99 
                     
                     
                     
Mutation Frequencies                   
                     
Drug 
Resistant 
CFU/ml Total CFU/ml 
Mutation 































V4207: ANAEROBIC                   
                     
Resistant CFU Counts                   
                     
INH 388 297 301 119 349 397 456 340 372 15 163 125 0 0 0 273 0 466 0 0 
RIF 14 12 13 0 64 8 10 7 5 13 19 2 20 14 17 16 0 31 11 28 
STR 183 184 56 51 39 164 209 98 252 121 194 72 246 116 179 108 172 183 1 3 
OFX 2 9 0 0 2 2 8 11 54 27 6 12 0 1 4 17 1 12 0 0 
KAN 153 69 67 84 135 144 214 96 267 161 134 60 236 86 93 100 124 201 63 106 
                     
                     
Mutation Frequencies                   
                     
Drug 
Resistant 
CFU/ml Total CFU/ml 
Mutation 































H37Rv: AEROBIC                   
                     
Resistant CFU Counts                   
                     
INH 432 411 321 222 304 374 397 296 315 318 259 0 369 520 402 0 345 350 351 286 
RIF 5 9 4 18 15 12 16 5 10 6 4 11 3 3 10 22 1 7 11 1 
OFX 16 31 40 4 10 2 38 19 9 12 5 64 15 45 18 9 10 6 10 13 
STR 80 86 72 259 202 146 110 86 138 201 48 66 101 145 127 129 224 112 163 146 
KAN 228 250 164 172 241 140 94 96 122 128 99 64 72 83 100 89 84 113 134 55 
                     
                     
Mutation Frequencies                   
                     
Drug 
Resistant 
CFU/ml Total CFU/ml 
Mutation 































H37Rv: ANAEROBIC                   
                     
Resistant CFU Counts                   
                     
INH 0 209 43 174 155 211 44 65 87 73 81 95 138 283 95 94 53 155 150 132 
RIF 12 9 16 4 8 8 10 26 4 24 11 15 16 10 6 18 5 11 7 7 
STR 5 74 0 95 140 20 46 29 8 25 0 135 0 4 12 9 26 107 139 24 
OFX 139 166 38 14 7 135 67 106 91 96 165 160 134 17 164 163 151 77 1 5 
KAN 50 20 26 39 36 63 62 95 39 74 31 8 80 35 107 27 1 1 0 0 
                     
                     
                     
Mutation Frequencies                   
                     
Drug 
Resistant 
CFU/ml Total CFU/ml 
Mutation 

























              
 
 
 
 
